Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
On April 6, 2023, Insmed (Nasdaq: INSM) announced the granting of inducement awards to 24 new employees as per NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase a total of 182,880 shares of common stock at an exercise price of $17.37, which corresponds to the closing trading price on the date of grant, April 3, 2023. The options feature a 10-year term and a four-year vesting schedule, with shares vesting incrementally over that period. Insmed is focused on transforming the lives of patients with serious and rare diseases, with its first commercial product approved in multiple regions to treat a chronic lung disease.
Insmed Incorporated (Nasdaq: INSM) has announced the completion of adult patient enrollment in its pivotal ASPEN study for brensocatib, a first-in-class treatment candidate for bronchiectasis. The Phase 3 study has enrolled over 1,700 patients aged 12 to 85 years, randomized into three groups for a 52-week treatment period. Topline data is expected in Q2 2024. Brensocatib, which has received Breakthrough Therapy Designation from the FDA, targets a market with no approved treatments and aims to alleviate the severe symptoms of bronchiectasis. The ongoing adolescent enrollment will not impact planned regulatory submissions.
Insmed, a biopharmaceutical company, announced eight presentations focusing on lung diseases at the American Thoracic Society (ATS) 2023 International Conference, scheduled for May 19-24, 2023, in Washington, D.C. Key highlights include:
- A qualitative interview study on amikacin liposome inhalation suspension (ARIKAYCE)
- Subgroup analysis of the Phase 2 WILLOW study on brensocatib in bronchiectasis patients
- Data on the hospitalization burden for patients with chronic obstructive pulmonary disease (COPD) and nontuberculous mycobacterial lung disease.
Insmed aims to address significant challenges in treating serious and rare lung diseases.
On March 3, 2023, Insmed announced the granting of inducement awards to 17 new employees as part of its hiring strategy. These awards, compliant with NASDAQ Listing Rule 5635(c)(4), involve options to purchase a total of 136,800 shares of Insmed common stock at an exercise price of $20.24 per share, the closing price on March 1, 2023. The options come with a 10-year term and a four-year vesting schedule, incentivizing employee retention and performance. Insmed focuses on transforming lives through therapies for serious and rare diseases.
Insmed, a biopharmaceutical company focused on rare diseases, announced its participation in two investor conferences. The first is the Cowen 43rd Annual Healthcare Conference, set for March 8, 2023, at 12:50 p.m. ET in Boston, followed by the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. ET in Miami. Both presentations will feature fireside chats and will be available for live webcast on the company's investor relations website, archived for 30 days post-event. Insmed is committed to advancing therapies for serious unmet medical needs.
Insmed (Nasdaq: INSM) reported a strong financial performance for Q4 and FY 2022, with revenues of $59.3 million and $245.4 million, respectively, reflecting a 30% annual growth, primarily driven by ARIKAYCE sales. The company completed patient screening in the Phase 3 ASPEN trial for brensocatib and expects topline results in Q2 2024. Insmed anticipates ARIKAYCE revenues to reach $285-$300 million in 2023. Despite these gains, the company reported a net loss of $160.1 million in Q4 2022. With $1.15 billion in cash reserves, Insmed is well-positioned for sustained investment in its clinical programs.
Insmed Incorporated (Nasdaq: INSM) will release its fourth quarter and full year 2022 financial results on February 23, 2023. A conference call for investors is scheduled for 8:30 a.m. ET on the same day to discuss these results and provide a business update. Interested parties can join the call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international), or by accessing the live webcast on the company's website. A replay will be available shortly after the event until March 25, 2023. Insmed is focused on serious and rare diseases, with its first therapy already approved in the U.S., Europe, and Japan.
Insmed Incorporated (Nasdaq: INSM) announced its participation in a fireside chat at the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 12:00 p.m. ET. The event aims to highlight Insmed's commitment to transforming lives through its innovative approaches to serious and rare diseases. The chat will be accessible via the investor relations section on the company's website and will be archived for 30 days post-event. Insmed's first product treats a debilitating lung disease, with ongoing development of therapies targeting unmet medical needs.
Insmed Incorporated (Nasdaq:INSM), a biopharmaceutical company, announced on February 3, 2023, the granting of inducement awards to 18 new employees under NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase a total of 240,010 shares at an exercise price of $21.62 per share, which reflects the closing price on the grant date. These options have a 10-year term and a four-year vesting schedule. Insmed's mission focuses on transforming the lives of patients suffering from serious and rare diseases, supported by a robust pipeline of investigational therapies.
On January 20, 2023, Insmed Incorporated (NASDAQ: INSM) announced the granting of inducement awards to 10 new employees as a material inducement for their employment. The awards, approved by the Compensation Committee, comprise options to purchase 107,580 shares at an exercise price of $19.18 per share, which aligns with the Nasdaq closing price on the grant date of January 3, 2023. The options have a 10-year term with a four-year vesting schedule, incentivizing long-term employment. Insmed focuses on therapies for serious diseases and has a pipeline targeting unmet medical needs, enhancing its market position.